Leaderboards/Sinusitis and nasal conditions

Sinusitis and nasal conditions

Last updated July 7, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Shweta Mallikarjun Revannavar
Jawaharlal Nehru Medical College
2
Brian J. Lipworth
University of Dundee
3
Junqin Bai
Northwestern University
4
Mrittika Sen
Sankara Nethralaya
5
Rik Johannes Leonardus van der Lans
University of Amsterdam
6
Nermin Morgan
Mansoura University
7
Aastha Maini
D.Y. Patil University
8
Shiru Cai
Beijing Tongren Hospital
9
Corrado Pelaia
Azienda Ospedaliero Universitario Mater Domini
10
Wael F. Ismaiel
Damietta University

Rising Stars Papers

1
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
New England Journal of Medicine|2025
145 cit.
2
Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis
Respirology|2024
35 cit.
3
Intravitreal Topotecan for Vitreous Seeds in Retinoblastoma
Ophthalmology|2024
17 cit.
4
Short-term therapeutic effectiveness of tezepelumab in patients with severe asthma: A real-world study
International Immunopharmacology|2025
11 cit.
5
Eosinophils are the dominant type2 marker for the current indication of biological treatment in severe uncontrolled chronic rhinosinusitis with nasal polyps
Rhinology Journal|2024
10 cit.
6
Difficult-To-Treat and Severe Asthma: Can Real-World Studies On Effectiveness of Biological Treatments Change the Lives of Patients?
Pragmatic and Observational Research|2024
7 cit.
7
Increased autoreactivity and maturity of EBI2+ antibody-secreting cells from nasal polyps
JCI Insight|2024
3 cit.
8
Effects of inhaled beclomethasone dipropionate/formoterol fumarate/glycopyrronium on diaphragmatic workload and lung function in uncontrolled asthma: a case report
Frontiers in Medicine|2024
2 cit.
9
Real-World Efficacy of Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium on Diaphragmatic Workload Assessed by Ultrasound and Lung Function in Patients with Uncontrolled Asthma
Advances in respiratory medicine|2025
1 cit.
10
Single‐Cell Profiling Identifies <scp>TNF</scp> ‐Responsive Circulating Eosinophils in Allergic Rhinitis
Allergy|2025
1 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Leda Mannent
Sanofi (France)
2
Abha Pandey
Banaras Hindu University
3
Aleksandra Wardzyńska
Medical University of Lodz
4
Stella E. Lee
Brigham and Women's Hospital
5
Viktoría Werkström
AstraZeneca (Sweden)
6
Elien Gevaert
University College Ghent
7
Wenyuan Li
Huazhong University of Science and Technology
8
Bobby A. Tajudeen
Rush University Medical Center
9
V K Vineeth
Nitte University
10
Ethan Soudry
Tel Aviv University

Emerging Leaders Papers

1
Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies
Allergy|2022
61 cit.
2
The Use of Artificial Intelligence to Improve Readability of Otolaryngology Patient Education Materials
Otolaryngology|2024
39 cit.
3
Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results
Annals of Otology Rhinology & Laryngology|2023
30 cit.
4
Comparative Performance of ChatGPT 3.5 and GPT4 on Rhinology Standardized Board Examination Questions
OTO Open|2024
21 cit.
5
Fractional Exhaled Nitric Oxide as a Marker of Mucosal Inflammation in Chronic Rhinosinusitis
American Journal of Rhinology and Allergy|2022
16 cit.
6
Histopathologic features of biologic therapy nonresponders in chronic rhinosinusitis with nasal polyposis
International Forum of Allergy & Rhinology|2023
13 cit.
7
Temperature‐controlled radiofrequency ablation for the treatment of chronic rhinitis: Two‐year outcomes from a prospective multicenter trial
International Forum of Allergy & Rhinology|2024
13 cit.
8
Histopathologic differences between adult and pediatric patients with chronic rhinosinusitis
International Forum of Allergy & Rhinology|2022
12 cit.
9
Recurrence Patterns and Efficacy of Surveillance Modalities for Sinonasal Malignancies
American Journal of Rhinology and Allergy|2022
11 cit.
10
New Concepts in Barrier Dysfunction in CRSwNP and Emerging Roles of Tezepelumab and Dupilumab
American Journal of Rhinology and Allergy|2023
11 cit.

Current Senior Leaders

Established & currently active

Current Senior Leaders Researchers

1
Claus Bachert
University Hospital Münster
2
Peter‐John Wormald
Health Net
3
Timothy L. Smith
Oregon Health & Science University
4
Luo Zhang
Hebei Medical University
5
David W. Kennedy
Thomas Jefferson University
6
Wytske J. Fokkens
Amsterdam University of Applied Sciences
7
Robert P. Schleimer
Northwestern University
8
Zheng Liu
Wuhan University
9
Richard J. Harvey
St Vincent’s Private Hospital Sydney
10
Ralph Metson
Massachusetts Eye and Ear Infirmary

Current Senior Leaders Papers

1
EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists
Rhinology Journal|2012
2.4k cit.
2
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
The Lancet|2019
1.5k cit.
3
EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists
Rhinology Journal|2012
1.2k cit.
4
EPOS2020: A Major Step Forward
Rhinology Journal|2020
1.2k cit.
5
Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers
Journal of Allergy and Clinical Immunology|2016
1.1k cit.
6
IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1
The Journal of Immunology|1992
830 cit.
7
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis
JAMA|2016
785 cit.
8
Differentiation of chronic sinus diseases by measurement of inflammatory mediators
Allergy|2006
779 cit.
9
Functional Endoscopic Sinus Surgery: Theory and Diagnostic Evaluation
Archives of Otolaryngology - Head and Neck Surgery|1985
763 cit.
10
Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma
Journal of Allergy and Clinical Immunology|2012
744 cit.

Reagents for Sinusitis and nasal conditions

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 65

Ret (E1N8X) Rabbit Monoclonal Antibody

#14556$177,413
View Evidence →
Cell Signaling Technology

USP13 (D4P3M) Rabbit Monoclonal Antibody

#12577$161,351
View Evidence →
Cell Signaling TechnologyEvidence 61

CLIC4 (D2A7D) Rabbit Monoclonal Antibody

#12644$161,351
View Evidence →

🌟 All-Time

Most validated

Acris AntibodiesEvidence 60

Mouse Anti-Canine Distemper Virus Monoclonal Antibody, Unconjugated, Clone 40026

#3CD10-8-1
View Evidence →
Acris AntibodiesEvidence 60

Mouse Anti-Canine Distemper Virus Monoclonal Antibody, Unconjugated, Clone 39937

#3CD10-5-4
View Evidence →
Acris Antibodies

Mouse Anti-CD154 / CD40L Monoclonal Antibody, Unconjugated Clone 2A3

#4CD40-2A3
View Evidence →